Home / Health / Kisqali Extends Life in Early Breast Cancer
Kisqali Extends Life in Early Breast Cancer
23 Oct
Summary
- Kisqali combined with hormone therapy reduced death risk.
- The study involved patients with early-stage breast cancer.
- Survival rates showed a significant improvement after six years.
Novartis AG's Kisqali has demonstrated a significant survival benefit for patients diagnosed with a common form of early-stage breast cancer. The findings suggest that Kisqali, when administered alongside standard hormone therapy, substantially improves long-term outcomes.
According to a recent study, the addition of Kisqali to existing hormone treatments reduced the risk of death by approximately 19% over a six-year period. This outcome is particularly encouraging as it pertains to the treatment of early-stage disease, aiming to prevent the cancer from returning.
The lead investigator of the study presented these pivotal results. The data reinforces the value of Kisqali as a therapeutic option for patients, potentially extending their lives and offering a more hopeful prognosis in the fight against breast cancer.
